Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)

Description:

The fragment TDQVPFSV is a gp100 epitope that is recognized in the context of HLA-A2 by tumor-infiltrating lymphocytes (TIL) in vivo. PMEL 17 could be a melanogenic enzyme.

Sequence:

ITDQVPFSV

General

References

Comments (0)

Name	Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)
Category	Cancer Research Peptides
One Letter Code	ITDQVPFSV
Three Letter Code	{Ile}{Thr}{Asp}{Gln}{Val}{Pro}{Phe}{Ser}{Val}
Molecular Weight	1005.140
Application	Antigen-presenting CellsCancer Research

Dudley, Mark E., et al. "T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes." Cancer journal (Sudbury, Mass.) 6.2 (2000): 69-77.

Velders, Markwin P., et al. "Identification of peptides for immunotherapy of cancer. It is still worth the effort." Critical Reviews™ in Immunology 18.1-2 (1998).

Salgaller, Michael L., et al. "Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides." Cancer research 56.20 (1996): 4749-4757.

Parkhurst, Maria R., et al. "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0201-binding residues." The Journal of Immunology 157.6 (1996): 2539-2548.

Salgaller, Michael L., et al. "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides." Cancer research 55.21 (1995): 4972-4979.